OpenAI acquires Orchestra Bio to expand Rosalind Life Sciences – Unite.AI tools

OpenAI has acquired Orchestra Bio, a company whose platform coordinates drug development work among biopharmaceutical teams, and is bringing the startup’s team and technology together with Rosalind, its AI models and tools for life sciences research. OpenAI announced the acquisition on October 20, 2026.

OpenAI said its goal is to help scientists make discoveries and manage the work needed to turn those discoveries into treatments that reach patients more quickly. According to the company, developing a new drug takes an average of 10 to 15 years from target discovery to regulatory approval in the United States, and the teams behind these programs must coordinate work between internal departments and external partners, often across disconnected systems. OpenAI describes the present moment as an inflection point where AI can take over these specialized tasks and complex workflows.

Integration with Rosalind

Rosalind is the life sciences brand of OpenAI. OpenAI describes GPT-Rosalind as a purpose-built model that helps scientists think about questions in biology and chemistry, and Rosalind Workbench as the layer that connects those capabilities with scientific tools and data so researchers can analyze results and plan experiments. Orchestra adds a team with expertise in biotechnology, software and artificial intelligence, along with a platform built to coordinate drug development. OpenAI said that together the organizations aim to build agents that connect scientific discoveries with the studies, decisions and next steps needed to advance a potential drug.

How the Orchestra platform works

Orchestra Bio has built its platform around a model where people and AI agents work together to advance anti-drug programs. Scientists and program leaders turn the tracking and monitoring of studies and campaigns over to agents, which OpenAI says frees them to guide the work, make decisions and address problems before they cause delays. According to OpenAI, a problem in one part of a pharmaceutical program can affect many others: a failed production batch, for example, can delay the start of a clinical trial. Orchestra agents identify the activities and timing affected by a problem, collect relevant information and compare response options; scientists and program leaders can then use that analysis to decide what to do next.

Orchestra Bio confirmed the acquisition on its website, saying it had founded the company four years earlier to help biotech and pharmaceutical teams advance their drug development programs. The company describes drug development as a process involving thousands of decisions and dependencies that affect discovery, preclinical, manufacturing and clinical work. In his definition, agents can do planning, orchestration, and analysis, leaving scientists and program leaders to focus on decisions that require their expertise. Orchestra Bio said it will join OpenAI “to continue our mission on an even greater scale” and thanked its customers, investors and supporters.

Access to Rosalind and reported benchmarks

Rosalind Workbench is a search preview, with an orchestrated set of scientific tools connected in a single workspace. It offers an Explore mode for general scientific questions, using the latest ChatGPT templates available to the user, and a Research mode that applies GPT-Rosalind to more complex biological questions, in-depth analyzes and advanced research workflows, with access via an inquiry process. Researchers can also use GPT-Rosalind within Codex to connect their scientific tools, data and evidence into research workflows that teams can review, share and reuse, while a GPT-Rosalind API caters to organizations looking to integrate life science reasoning into their own research applications, internal tools and governed workflows. Access to the API is subject to eligibility verification and organizational approval.

OpenAI’s product page reports benchmark results for the model on life sciences research tasks, expressed as performance increases per token: 53.7% on Genebench, 18.0% on Medchem Bench, 19.6% on Labworkbench, and 4.42% on LifeSci Bench. The page lists supported uses that include prioritizing biological targets, protein engineering, synthesizing evidence across papers and experiments, analyzing unstructured experimental results, and saving workflows that teams can inspect, share, and reuse.

Pharmaceutical partnerships and access programs

OpenAI said its partnership with Novo Nordisk aims to translate the drugmaker’s scale and scientific expertise into faster R&D and commercial execution, while maintaining strong governance, and that at Moderna, AI is helping teams transform insights from complex data into experimental workflows, with the potential to accelerate R&D. In a statement posted on OpenAI’s Rosalind page, Mike Doustdar, CEO and president of Novo Nordisk, said: “Our partnership with OpenAI will help translate this scale into faster R&D and commercial execution, while maintaining the governance our patients and society expect.”

OpenAI also lists structured access paths beyond enterprise customers. The Rosalind Academic Plan offers eligible labs sponsored access to GPT-Rosalind and life science discovery tools. An enterprise option brings GPT-Rosalind into approved research workstreams with governance review and enterprise-level implementation controls, while government and public health teams can request revised access for research, preparedness and resilience work within what OpenAI describes as clear public benefit boundaries. A separate Rosalind Biodefense program supports trusted developers and public health teams building defensive applications with GPT-Rosalind, with focus areas including early detection, preparedness, diagnostics, response and medical countermeasures.

OpenAI said its broader vision is for artificial intelligence to help scientists across the entire drug discovery and development process, and described the collaboration between Orchestra Bio and Rosalind as a step toward that vision.